Keywords: pdl, hit, asthma, drug, failure, protein, design
PDL is hit by asthma drug failure
Article | 19 May 2003
Protein Design Labs has reported that data from a Phase IIa trial of its humanized anti-interleukin-4 antibody in steroid-naive, mild-to-moderate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
